Deep Track Capital LP Sells 100,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Deep Track Capital LP lowered its stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 867,000 shares of the company’s stock after selling 100,000 shares during the period. Deep Track Capital LP owned 8.34% of Avalo Therapeutics worth $6,442,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of AVTX. Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 1,123.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock worth $4,092,000 after purchasing an additional 505,765 shares during the period. Geode Capital Management LLC increased its holdings in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after acquiring an additional 94,742 shares during the period. Allostery Investments LP purchased a new position in Avalo Therapeutics during the fourth quarter worth about $545,000. BVF Inc. IL increased its position in shares of Avalo Therapeutics by 7.2% in the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock worth $7,703,000 after purchasing an additional 69,679 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVTX has been the topic of several research reports. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Piper Sandler began coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $36.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Trading Down 5.6 %

Shares of NASDAQ:AVTX opened at $4.74 on Wednesday. Avalo Therapeutics, Inc. has a 12-month low of $4.15 and a 12-month high of $16.00. The stock has a fifty day simple moving average of $6.30 and a two-hundred day simple moving average of $8.29.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.